Initial experience with CMC-544 (inotuzumab ozogamicin) in pediatric patients with relapsed B-cell acute lymphoblastic leukemia
Author:
Affiliation:
1. Department of Pediatrics; The University of Texas MD Anderson Cancer Center; Texas
2. Department of Leukemia; The University of Texas MD Anderson Cancer Center; Texas
Publisher
Wiley
Subject
Oncology,Hematology,Pediatrics, Perinatology and Child Health
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1002/pbc.24721/fullpdf
Reference17 articles.
1. Long-term follow-up of relapsed childhood acute lymphoblastic leukaema;Chessells;Br J Haematol,2003
2. Treatment of childhood acute lymphoblastic leukemia in second remission with allogeneic bone marrow transplantation and chemotherapy: Ten-year experience of the Italian Bone Marrow Transplantation Group and the Italian Pediatric Hematology Oncology Association;Uderzo;J Clin Oncol,1995
3. How I treat relapsed childhood acute lymphoblastic leukemia;Locatelli;Blood,2012
4. Long-term outcome in children with relapsed ALL by risk-stratified salvage therapy: Results of trial acute lymphoblastic leukemia-relapse study of the Berlin-Frankfurt-Munster Group 87;Einsiedel;J Clin Oncol,2005
5. Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: Results of trial ALL-REZ BFM 90;Tallen;J Clin Oncol,2010
Cited by 58 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Inotuzumab Ozogamicin: First Pediatric Approval;Pediatric Drugs;2024-05-23
2. A multicenter study of posttransplantation low-dose inotuzumab ozogamicin to prevent relapse of acute lymphoblastic leukemia;Blood Advances;2024-03-13
3. Inotuzumab ozogamicin in B-cell precursor acute lymphoblastic leukemia: efficacy, toxicity, and practical considerations;Frontiers in Immunology;2023-08-03
4. Pediatric Acute Lymphoblastic Leukemia Emerging Therapies—From Pathway to Target;International Journal of Molecular Sciences;2023-02-28
5. Infectious Complications of Targeted Therapies in Children with Leukemias and Lymphomas;Cancers;2022-10-14
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3